Enlicitide
Merck's investigational oral macrocyclic peptide PCSK9 inhibitor — the first oral PCSK9 inhibitor to reach Phase 3, designed to compete with monoclonal antibody PCSK9 inhibitors (evolocumab, alirocumab) on convenience and to compete with statins on LDL-C reduction.
What is Enlicitide?
Enlicitide (development code MK-0616, INN enlicitide decanoate) is Merck's investigational oral macrocyclic peptide that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), the protein that promotes LDL receptor degradation in hepatocytes. PCSK9 inhibition has been clinically transformative for hypercholesterolemia and cardiovascular risk reduction via the injectable monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent) — both Phase 3-validated with cardiovascular outcomes benefit but limited by injection burden and cost. Enlicitide aims to deliver comparable LDL-C reductions through a once-daily oral peptide, addressing the major access barrier of the antibody class. Merck's CORALreef Phase 3 program enrolled tens of thousands of patients across hypercholesterolemia subpopulations (statin-treated, statin-intolerant, ASCVD secondary prevention) and read out across 2024–2026 with LDL-C reductions in the 50–66% range, supporting regulatory filings expected in 2026–2027. As of mid-2026, enlicitide is not yet FDA-approved but is the highest-profile oral peptide in late-stage cardiovascular development.
What Enlicitide Is Investigated For
Enlicitide is Merck's investigational oral macrocyclic peptide PCSK9 inhibitor — the first peptide of its class to reach Phase 3. Pivotal trial results from the CORALreef program (2025–2026) demonstrate LDL-C reductions of approximately 50–66% from baseline, comparable to monoclonal antibody PCSK9 inhibitors (evolocumab, alirocumab) but with the major practical advantage of once-daily oral dosing. The strongest evidence is from the multiple Phase 3 CORALreef trials in hypercholesterolemia (CORALreef Lipids), statin-intolerance (CORALreef Athero), and adjunctive to statins; results published in NEJM, JACC, and Eur Heart J in 2025–2026. The honest caveats: cardiovascular outcomes data (parallel to the FOURIER/ODYSSEY trials for the antibodies) is anticipated in 2027+ rather than concurrent with approval, and the long-term safety of macrocyclic peptide PCSK9 inhibition over years remains to be established. Enlicitide is not yet FDA-approved but is anticipated to enter the cardiovascular treatment landscape as the first oral PCSK9 inhibitor in 2026–2027.
History & Discovery
PCSK9 was identified as a therapeutic target in the early 2000s following population genetics work showing that loss-of-function PCSK9 variants are associated with substantially lower LDL-C and reduced cardiovascular events. The monoclonal antibody PCSK9 inhibitors evolocumab (Repatha, Amgen) and alirocumab (Praluent, Sanofi/Regeneron) reached FDA approval in 2015 with the FOURIER (2017) and ODYSSEY OUTCOMES (2018) trials establishing cardiovascular outcomes benefit. Inclisiran (Leqvio, Novartis), an siRNA against PCSK9, followed in 2021 with twice-yearly dosing. The oral PCSK9 inhibitor challenge — historically considered intractable because of the protein-protein interaction surface and the difficulty of oral peptide delivery — was tackled by Merck's macrocyclic peptide platform. MK-0616 (the development code for enlicitide) emerged from medicinal chemistry optimization targeting the PCSK9-LDLR binding interface, with the decanoate fatty acid modification enhancing intestinal permeability. Phase 1 demonstrated LDL-C reductions of 65% (Johns et al. 2023). The Phase 3 CORALreef program began enrollment in 2023 and read out across 2024–2026 in multiple subpopulations. Regulatory filings began in 2026, with anticipated FDA approval in 2026–2027 making enlicitide the first oral PCSK9 inhibitor.
How It Works
Enlicitide is a pill that blocks PCSK9, a protein that destroys the liver's LDL receptors. By blocking PCSK9, more LDL receptors stay on liver cells, pulling more bad cholesterol out of the blood and lowering LDL-C levels by half or more. The mechanism is identical to the injectable PCSK9 antibodies (Repatha, Praluent) but delivered as a daily oral pill.
PCSK9 binds the LDL receptor (LDLR) at the hepatocyte cell surface and targets the LDLR-PCSK9 complex for lysosomal degradation, preventing LDL receptor recycling and reducing the liver's capacity to clear circulating LDL. Inhibiting PCSK9 — whether by monoclonal antibody (evolocumab, alirocumab), siRNA (inclisiran), or now macrocyclic peptide (enlicitide) — preserves LDL receptor recycling, increases hepatic LDL-C uptake, and reduces serum LDL-C dramatically. Enlicitide is a macrocyclic peptide that binds PCSK9 at its LDLR-binding interface, preventing PCSK9 from engaging the LDL receptor. The molecule's design — a constrained cyclic structure with optimized hydrophobic and polar properties — enables oral absorption that linear peptides cannot achieve. The decanoate prodrug (enlicitide decanoate) further enhances intestinal permeability through a 10-carbon fatty acid modification that is cleaved after absorption. A 2026 Science paper (Cosgrove et al.) described the biocatalytic cascade manufacturing approach that enabled production at scale, an important consideration for a daily oral drug.
Evidence Snapshot
Human Clinical Evidence
Strong. Multiple Phase 3 trials in the CORALreef program have read out across 2024–2026 in hypercholesterolemia, statin-intolerance, and statin-adjunct populations, with LDL-C reductions of 50–66% from baseline. Recent meta-analyses include enlicitide alongside inclisiran and antibody PCSK9 inhibitors in lipoprotein(a) lowering.
Animal / Preclinical
Comprehensive. PCSK9 inhibition biology is among the most thoroughly characterized in cardiovascular medicine, and macrocyclic peptide drug design has been validated mechanistically.
Mechanistic Rationale
Very strong. PCSK9 inhibition is one of the best-validated cardiovascular therapeutic targets, with parallel evidence from monoclonal antibodies, siRNA, and now peptides.
Research Gaps & Open Questions
What the current literature has not yet settled about Enlicitide:
- 01Cardiovascular outcomes data — parallel to FOURIER and ODYSSEY OUTCOMES for the antibody class — is anticipated in 2027+ but not concurrent with regulatory approval, so initial use will rely on LDL-C as surrogate.
- 02Long-term safety beyond Phase 3 duration — macrocyclic peptide PCSK9 inhibition is novel and long-term safety profiles will accumulate over years post-approval.
- 03Comparative effectiveness vs. monoclonal antibody PCSK9 inhibitors in head-to-head outcomes data is not yet available.
- 04Cost and access — once approved, real-world reimbursement and adherence patterns will determine the practical impact compared to existing PCSK9 antibodies.
- 05Pediatric use — particularly relevant for familial hypercholesterolemia, has not been characterized.
- 06Use in pregnancy and lactation has not been studied.
Forms & Administration
Once-daily oral tablet. Investigational. Not commercially available as of mid-2026 — anticipated launch following FDA filing and regulatory review in 2026–2027.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Phase 3 dosing in the CORALreef program has used enlicitide decanoate at 6, 12, 18, or 30 mg once daily by mouth. The 18 mg or 30 mg doses produced the largest LDL-C reductions (50–66% from baseline). Final commercial dose is anticipated to be in this range.
Frequency
Once-daily oral administration, with or without food (specific food-effect dosing recommendations pending labeling).
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Chronic indefinite therapy — like statins and antibody PCSK9 inhibitors, enlicitide is intended for chronic LDL-C management with cardiovascular risk reduction as the long-term goal. There is no cycling.
Protocol Notes
Once approved, enlicitide will likely be positioned for: (1) patients on maximally tolerated statins who need additional LDL-C lowering, (2) statin-intolerant patients needing alternative LDL-C lowering, and (3) secondary prevention in ASCVD where the antibody PCSK9 class has been positioned. The oral route should expand access compared to the antibody class (which requires monthly subcutaneous injection) and may produce more rapid uptake than inclisiran (twice-yearly injection by healthcare provider). Long-term outcomes data (parallel to FOURIER for evolocumab and ODYSSEY OUTCOMES for alirocumab) is anticipated in 2027+. Until those data are available, regulatory approval will be based on LDL-C reduction as a surrogate endpoint, consistent with the pathway for inclisiran and other lipid-lowering agents.
Enlicitide is investigational as of mid-2026 and not FDA-approved. Treatment of hypercholesterolemia requires individualized clinical assessment by a primary care clinician or cardiologist. This information is for educational reference, not treatment direction.
Timeline of Effects
Onset
LDL-C reductions detectable within 2–4 weeks of starting therapy, with the majority of effect reached by 4–8 weeks. Steady-state pharmacokinetics with daily dosing is established within roughly a week.
Peak Effect
Maximum LDL-C reduction at 8–12 weeks. The CORALreef Phase 3 trials measured primary endpoints at 24 weeks.
After Discontinuation
LDL-C returns toward baseline over weeks following discontinuation as PCSK9 levels recover and LDL receptor recycling normalizes. Pharmacokinetic half-life supports the daily dosing regimen.
Common Questions
Who Enlicitide Is NOT For
- •Pregnancy — limited safety data; LDL-C lowering during pregnancy is not generally recommended; use deferred unless benefit clearly outweighs risk.
- •Breastfeeding — limited data; pediatric exposure via breast milk not characterized.
- •Pediatric use — Phase 3 program focused on adults; pediatric efficacy and safety not established.
- •Known hypersensitivity to macrocyclic peptides or formulation excipients.
- •Active liver disease — liver function should be assessed at baseline.
Drug & Supplement Interactions
Enlicitide as a macrocyclic peptide may have specific drug-interaction patterns relevant to its absorption and metabolism. Co-administration with cyclosporine, certain protease inhibitors, or other macrocyclic immunosuppressants may produce competition for transporters or absorption pathways; specific labeling will follow regulatory review. For the clinical use case (LDL-C management), concurrent statin therapy is the expected pattern in most patients. Statins and PCSK9 inhibitors are mechanistically complementary and produce additive LDL-C reduction. Ezetimibe combinations have been studied in CORALreef. Combination with inclisiran is unusual — generally one PCSK9-targeting agent is used at a time. Concurrent fibrates, niacin, and bile acid sequestrants do not have meaningful interactions but provide modest additional LDL-C benefit. Statin-related muscle symptoms have not been characteristic of enlicitide Phase 3, given its non-statin mechanism.
Safety Profile
Common Side Effects
Cautions
- • Investigational — not FDA-approved as of mid-2026
- • Long-term cardiovascular outcomes data still accruing
- • Pregnancy and breastfeeding safety not established
What We Don't Know
Phase 3 efficacy is well-characterized but long-term cardiovascular outcomes (vs. FOURIER for evolocumab) are not yet available. Real-world cost and access remain to be established post-approval.
Legal Status
United States
Investigational — not FDA-approved as of mid-2026. Merck has filed for FDA approval, with anticipated decision in 2026–2027. Will be a prescription-only medication once approved. Not a controlled substance.
International
Investigational across major regulators as of mid-2026. EMA, MHRA, and other major agencies are reviewing parallel submissions.
Sports & Competition
Not specifically named on the WADA Prohibited List. PCSK9 inhibitors do not provide performance-enhancing effects and would not be expected to be prohibited.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Enlicitide is just another statin in pill form.
Reality
Enlicitide is a PCSK9 inhibitor, not a statin. Statins (atorvastatin, rosuvastatin, etc.) inhibit HMG-CoA reductase to reduce hepatic cholesterol synthesis. PCSK9 inhibitors prevent LDL receptor degradation, allowing more LDL-C clearance. They are complementary mechanisms often used together, but pharmacologically distinct.
Myth
Oral peptides don't work because they get digested.
Reality
Linear peptides do generally not survive oral administration, but macrocyclic peptide engineering with optimized chemistry can produce oral bioavailability. Cyclosporine has been an oral peptide for decades. Enlicitide's macrocyclic structure and decanoate prodrug enable adequate oral absorption to achieve PCSK9-inhibiting plasma levels.
Myth
If enlicitide is approved, evolocumab and alirocumab become obsolete.
Reality
Antibody PCSK9 inhibitors have established cardiovascular outcomes data (FOURIER, ODYSSEY OUTCOMES) that enlicitide will not have at approval. They will remain relevant for patients who have demonstrated efficacy and tolerability on them, for patients with adherence concerns favoring monthly injection, and for patients participating in established cost-coverage programs. Oral enlicitide will likely complement rather than replace the antibody class.
Published Research
7 studiesNew frontiers in the treatment of hypercholesterolaemia: oral inhibition of PCSK9
European Heart Journal Supplements 2026 review of oral PCSK9 inhibition centered on enlicitide decanoate. Key claim: enlicitide decanoate produces substantial LDL-C reductions through orally-deliverable macrocyclic peptide chemistry. The reference orientation paper for understanding where enlicitide fits in the PCSK9-targeting landscape.
Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide
Trial of the Oral PCSK9 Inhibitor Enlicitide. Reply
Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial
JACC 2026 Phase 3 head-to-head trial demonstrating enlicitide produced greater reductions in LDL-C, ApoB, and non-HDL-C than other oral nonstatin therapies. Pivotal evidence for the oral PCSK9 use case.
Overcoming Challenges in the Metabolism of Peptide Therapeutics: Strategies and Case Studies for Clinical Success
Oral PCSK9 Inhibitors: Will They Work?
Quick Facts
- Class
- Macrocyclic Peptide PCSK9 Inhibitor
- Tier
- B
- Evidence
- Strong
- Safety
- Moderate Data
- Updated
- May 2026
- Citations
- 7PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.